Publicaciones en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (10)

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

2019

  1. Dissemination of health technologies: Trends in the use of diagnostic test in breast cancer screening

    Journal of Healthcare Quality Research, Vol. 34, Núm. 4, pp. 177-184

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2014

  1. Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82

2013

  1. A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 31, Núm. SUPPL.75

  2. Evidence of association of the NLRP1 gene with giant cell arteritis

    Annals of the Rheumatic Diseases

  3. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

2012

  1. Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population

    Clinical and Experimental Rheumatology, Vol. 30, Núm. SUPPL. 70

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279